Displaying One Session

Channel 1 Proffered paper
Date
Fri, 07.05.2021
Time
17:15 - 18:30
Room
Channel 1
Best abstracts Proffered paper

Live introduction (ID 232)

Lecture Time
17:15 - 17:16
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30
Best abstracts Proffered paper

41O - Nine weeks vs 1 year adjuvant trastuzumab: long term outcomes of the ShortHER randomised trial. (ID 233)

Presentation Number
41O
Lecture Time
17:16 - 17:28
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30

Abstract

Background

The ShortHER trial randomised 1254 patients with HER2+ early breast cancer to chemotherapy plus 9 weeks vs 1 year adjuvant trastuzumab. The study was designed as a non inferiority trial with a DFS hazard ratio (HR) < 1.29 as the non inferiority margin. At the event driven analysis, the HR for DFS was 1.13 (90% CI 0.89-1.42) therefore non inferiority could not be claimed (P Conte et al, Ann Oncol 29:2328-2333). Here we report the overall survival (co-primary end point of the study) and the updated DFS curves according to risk categories of long vs short treatment arms.

Methods

Study design, patient characteristics and event-driven DFS analysis have been previoulsy reported. This analysis reports the overall survival and the updated DFS curves according to HR status and three risk categories: low risk (pT< 2cm and pN0), intermediate risk (pT < 2cm and 1-3 pN+ or pT > 2cm and 0-3 pN+) and high risk (any pT and 4+ pN+).

Results

At a median follow up of 8.7 years, 237 DFS events have occurred: 121 in the short and 116 in the long arm respectively (HR 1.09; 90% CI 0.88-1.35). DFS according to post-hoc risk groups are: low risk (37.2% of the study population) HR 0.91 (90% CI 0.60-1.38); intermediate risk (46.7% of the study population) HR 0.88 (90% CI 0.63-1.21); high risk (15.2% of the study population) HR 2.06 (90% CI 1.36-3.13). DFS according to HR status are: HR+ HR 1.11 (90% CI 0.85-1.46); HR- HR 1.06 (90% CI 0.75-1.50). 109 deaths have been reported (58 in the short, 51 in the long arm). The 9 yrs OS is 90% in the short and 91% in the long arm (HR 1.18; 90% CI 0.86-1.62).

Conclusions

The updated DFS and OS analysis of the ShortHER trial confirm the favourable long-term results of 9 weeks adjuvant trastuzumab in the patients with low and intermediate risk factors. These patients represent 83.9 % of the ShortHER study population and the majority of the patients treated in daily practice. One-year trastuzumab remains standard. On the basis of these results however, a shorter trastuzumab administration could be an option in case of limited access to trastuzumab. Our data are reassuring for patients who have to discontinue trastuzumab due to a decline in LVEF.

Clinical trial identification

EUDRACT number: 2007-004326-25; NCI number: NCT00629278.

Legal entity responsible for the study

University of Padua, University of Modena and Reggio Emilia.

Funding

AIFA Agenzia Italiana del Farmaco (grant number FARM62MC97).

Disclosure

P.F. Conte: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): roche; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Merck kga; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Speaker Bureau/Expert testimony: Lilly. A. Frassoldati: Advisory/Consultancy, Travel/Accommodation/Expenses: roche; Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: Daiichi; Advisory/Consultancy: astrazeneca; Travel/Accommodation/Expenses: Lilly; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer. O. Garrone: Advisory/Consultancy: Eisai; Advisory/Consultancy: Eli Lilly; Speaker Bureau/Expert testimony: Novartis. L. Cavanna: Speaker Bureau/Expert testimony: AstraZeneca; Travel/Accommodation/Expenses: Celgene; Travel/Accommodation/Expenses: MSD; Travel/Accommodation/Expenses: Ibsen; Speaker Bureau/Expert testimony: Pfizer. A. Musolino: Honoraria (self), Research grant/Funding (institution): Eisai; Honoraria (self), Research grant/Funding (institution): Roche; Honoraria (self): Macrogenics; Honoraria (self): Merck; Honoraria (self), Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Pfizer. A. Ferro: Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Eli Lilly. C. Zamagni: Advisory/Consultancy: Eisai; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Expenses: PharmaMar; Advisory/Consultancy: Amgen; Advisory/Consultancy, Travel/Accommodation/Expenses: Tesaro; Honoraria (self): Quintiles MS; Travel/Accommodation/Expenses: Pierre Fabre; Advisory/Consultancy: Gentili; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Teva; Research grant/Funding (institution): Medivation; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Array Biopharma; Research grant/Funding (institution): morphotek; Research grant/Funding (institution): synthon; Research grant/Funding (institution): Seattle Genetics; Advisory/Consultancy: Celgene. M.V. Dieci: Advisory/Consultancy: Novartis; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy: Celgene; Advisory/Consultancy: Genomic Health. V. Guarneri: Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Advisory/Consultancy: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis. All other authors have declared no conflicts of interest.

Collapse
Best abstracts Proffered paper

42O - Biomarker analysis from KAITLIN, a randomised phase 3 study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (ID 234)

Presentation Number
42O
Lecture Time
17:28 - 17:40
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30

Abstract

Background

KAITLIN (NCT01966471) compared adjuvant AC-KP versus AC-THP in patients with HER2-positive, high-risk EBC. A preplanned exploratory analysis assessed the relationship between invasive disease-free survival (IDFS) and biomarkers (BMs) potentially related to response.

Methods

Baseline tumor samples were used for central assessment of HER2 and pre-specified BMs including HER2 mRNA expression and PTEN IHC expression by median (med) cutoff, and activating PIK3CA hotspot mutations. The effect of treatment and BMs on IDFS was assessed via descriptive analyses.

Results

BMs were well balanced between treatment arms. No BM subgroup showed more benefit from AC-KP than AC-THP. A trend for reduced benefit with AC-KP vs AC-THP was seen in the HER2 <30% expression and 4 to <6 gene copy number subgroups (Table). No clear prognostic relationships were identified in pooled arms (PIK3CA mut vs non-mut HR=1.27 [0.92–1.74]; HER2 IHC3+ vs IHC2+ HR=0.82 [0.55–1.23]; HER2 mRNA ≥ vs < med HR=0.76 [0.56–1.03]).

AC-THP (n=918) AC-KP (n=928) HR (95% CI)
BM* n 3-yr IDFS, % n 3-yr IDFS, %
HER2 IHC 2+ 3+ 130781 95.294.1 127791 93.593.2 1.34 (0.65–2.80)0.89 (0.64–1.24)
HER2 gene ratio 2 to <4 ≥4 200693 95.994.1 186714 92.893.1 1.29 (0.71–2.35)0.91 (0.64–1.30)
HER2 gene copy number 4 to <6 ≥6 78809 97.494.2 86811 87.093.8 2.77 (1.08–7.09)0.85 (0.61–1.18)
HER2 mRNA <Med ≥Med 446436 94.594.6 442454 91.794.3 1.18 (0.79–1.77)0.86 (0.54–1.36)
HER2 IHC Expression <30% Expression ≥30% 67851 97.094.0 70858 91.193.2 3.41 (1.10–10.60)0.87 (0.63–1.18)
PIK3CA Mut Not mut 276606 95.993.7 249645 89.794.1 1.31 (0.78–2.20)0.91 (0.62–1.32)
PTEN <Med ≥Med 329479 95.794.4 348468 91.494.7 1.39 (0.87–2.22)0.84 (0.53–1.34)

*HER2 IHC0/1+ (n=14), HER2 gene copy number <4 (n=20) and gene ratio <2 (n=11) excluded.

Conclusions

Consistent with the primary study results, AC-KP did not reduce the risk of an IDFS event compared to AC-THP in any BM subgroup. HP + chemotherapy remains the standard of care for those with high-risk HER2-positive EBC. No BMs had prognostic value in the pooled arm analyses.

Clinical trial identification

NCT01966471.

Editorial acknowledgement

Support for third-party writing assistance was provided by Tracy McNally, PhD and Holly Strausbaugh, PhD (Twist Medical, Burlingame, CA, USA), funded by F. Hoffmann-La Roche.

Legal entity responsible for the study

F. Hoffmann-La Roche.

Funding

F. Hoffmann-La Roche.

Disclosure

O. Metzger: Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AbbVie; Advisory/Consultancy, Research grant/Funding (institution): G1 Therapeutics; Research grant/Funding (institution): Roche; Research grant/Funding (institution), Non-remunerated activity/ies, Co-chair Advisory Board: Pfizer. C. Lambertini: Full/Part-time employment: F. Hoffmann - La Roche Ltd. I.E. Krop: Honoraria (self), Research grant/Funding (institution): Genentech/Roche; Research grant/Funding (institution): Pfizer; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Daiichi Sankyo; Honoraria (self): Macrogenics; Honoraria (self): Seattle Genetics; Honoraria (self): Celltrion; Honoraria (self): Merck; Honoraria (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self): Context Therapeutics. G. Lewis Phillips: Full/Part-time employment: Genentech, Inc; Shareholder/Stockholder/Stock options: F. Hoffmann - La Roche Ltd. C.M. Perou: Advisory/Consultancy, Leadership role, Shareholder/Stockholder/Stock options, Licensing/Royalties: Bioclassifier LLC; Advisory/Consultancy, Shareholder/Stockholder/Stock options, Licensing/Royalties, Officer/Board of Directors: GeneCentric Therapeutics. F. Symmans: Shareholder/Stockholder/Stock options, Licensing/Royalties, Founder shares, licensed intellectual property: Delphi Diagnostics; Shareholder/Stockholder/Stock options: IONIS Pharmaceuticals; Shareholder/Stockholder/Stock options: Eiger Pharmaceuticals. I. Melero: Honoraria (self), Research grant/Funding (institution): Roche/Genentech; Honoraria (self), Research grant/Funding (institution): BMS; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self): Alligator Bioscience; Honoraria (self): Bayer; Honoraria (self): Tusk Therapeutics; Honoraria (self): Gossamer Bio; Honoraria (self): Amunix; Honoraria (self): Replimune; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Medincell; Honoraria (self): Monopteros Therapeutics; Honoraria (self): Molecular Partners; Honoraria (self): Biontech; Honoraria (self): PharmaMar. N. Harbeck: Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Pierre Fabre; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche. E.P. Winer: Research grant/Funding (institution): AstraZeneca; Honoraria (self), Advisory/Consultancy: Carrick Therapeutics; Honoraria (self), Advisory/Consultancy: G1 Therapeutics; Honoraria (self), Research grant/Funding (institution): Genentech/Roche; Honoraria (self), Advisory/Consultancy: Genomic Health; Honoraria (self), Advisory/Consultancy: GSK; Honoraria (self), Advisory/Consultancy: Jounce; Honoraria (self), Advisory/Consultancy: Leap; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/Consultancy: Syros; Honoraria (self), Advisory/Consultancy: Zymeworks. S-A. Im: Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: AstraZeneca; Honoraria (self), Advisory/Consultancy: Amgen; Honoraria (self), Advisory/Consultancy: Eisai; Honoraria (self), Advisory/Consultancy: Hanmi; Honoraria (self), Advisory/Consultancy: Lilly; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Novartis; Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Non-remunerated activity/ies, Investigational agent for trial: Dae Woong. C.H. Barrios: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Amgen; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): GlaxoSmithKline; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Roche/Genentech; Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Sanofi; Research grant/Funding (institution): Taiho Pharmaceutical; Research grant/Funding (institution): Mylan; Research grant/Funding (institution): Merrimack; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Bayer; Research grant/Funding (institution): Astellas Pharma; Honoraria (self), Advisory/Consultancy: Eisai; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Abraxis Biosciences, BioMarin, LEO Pharma, AbbVie, Merck, and Millennium; Research grant/Funding (institution): AB Science, Asana Biosciences, Medivation, Exelixis, and Imclone Systems. H. Bonnefoi: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Non-remunerated activity/ies: Daiichi. J.R. Gralow: Honoraria (self): Genentech/Roche; Honoraria (self): Pfizer; Honoraria (self): Puma; Honoraria (self): AstraZeneca; Honoraria (self): Immunomedics; Honoraria (self): Genomic Health; Honoraria (self): Novartis; Honoraria (self): Sandoz/Hexal; Honoraria (self): Radius; Honoraria (self): Inbiomotion. L. Gianni: Advisory/Consultancy: Hexal Sandoz; Advisory/Consultancy: Seattle Genomics; Advisory/Consultancy: Synthon; Honoraria (self), Advisory/Consultancy: Zymeworks; Advisory/Consultancy: Sanofi-Aventis; Advisory/Consultancy: Forty Seven (CD47); Advisory/Consultancy: Genenta; Advisory/Consultancy: METIS Precision Medicine; Advisory/Consultancy: Novartis; Advisory/Consultancy: Odonate Therapeutics; Honoraria (self), Advisory/Consultancy: Revolution Medicine; Advisory/Consultancy: Synaffix; Advisory/Consultancy: Menarini Ricerche; Advisory/Consultancy: Amgen; Advisory/Consultancy: Biomedical Insights Inc.; Honoraria (self): Daiichi Sankyo; Licensing/Royalties, Co-inventor of European Patent Application N. 12195182.6 and 12196177.5 titled \"PDL-1 expression in anti-HER2 therapy\": Roche. M. Toi: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Chugai, Takeda, Pfizer, Taiho, Eisai, AstraZeneca, Shimadzo, Yakult, Nippon Kayaku; Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (self): Kyowa-Kirin, Daiichi Sankyo; Research grant/Funding (institution): Astellas, AFI Technologies, JBCRG Association, Astehnologies, Luxonos, Shionogi, GL Science; Honoraria (self), Advisory/Consultancy, Speaker Bureau/Expert testimony: Eli Lilly; Honoraria (self), Speaker Bureau/Expert testimony: MSD, Exact Science, Novartis; Honoraria (self), Advisory/Consultancy: Konica Minolta, BMS; Advisory/Consultancy: Athenex Oncology, Bertis, Terumo, Kansai Medical Net. S.M. Swain: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses, support for third party medical writing: Roche/Genentech; Honoraria (self), Advisory/Consultancy: Exact Sciences (Genomic Health); Honoraria (self), Advisory/Consultancy: Molecular Templates; Honoraria (self), Advisory/Consultancy: Silverback Therapeutics; Honoraria (self), Advisory/Consultancy: Tocagen; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Eli Lilly; Honoraria (self), Advisory/Consultancy: Natera; Honoraria (self), Advisory/Consultancy: Athenex; Honoraria (self), Advisory/Consultancy: Bejing Medical Foundation; Research grant/Funding (institution): Kailos Genetics; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/Expenses: Caris Life Sciences; Advisory/Consultancy, Scientific Advisory Board: Inivata. T. Boulet: Full/Part-time employment, Employee from Parexel International GmbH contracted by Roche for Statistical services: F. Hoffmann-La Roche Ltd. C. Song: Shareholder/Stockholder/Stock options, Full/Part-time employment: Roche/Genentech. S. de Haas: Shareholder/Stockholder/Stock options, Full/Part-time employment: F. Hoffmann-La Roche Ltd. All other authors have declared no conflicts of interest.

Collapse
Best abstracts Proffered paper

43O - Pertuzumab/Trastuzumab in Early Stage HER2-positive Breast Cancer: 5-year and Final Analysis of the BERENICE Trial (ID 235)

Presentation Number
43O
Lecture Time
17:40 - 17:52
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30

Abstract

Background

BERENICE was designed to establish the cardiac safety of neoadjuvant pertuzumab/trastuzumab (PH) with anthracycline-containing chemotherapies (primary objective). Here we report the 5-year outcomes at end-of-study (clinical cut-off date: 25/08/2020), including additional safety and efficacy data (secondary objectives).

Methods

BERENICE was a multicenter, open-label, non-comparative phase II trial. Patients with stage IIA to III HER2-positive breast cancer and a left ventricular ejection fraction (LVEF) ≥55% were allocated per physician's choice to cohort A (dose-dense doxorubicin/cyclophosphamide every 2 weeks [q2w] x 4 → paclitaxel q1w x 12) or cohort B (5-fluorouracil, epirubicin, cyclophosphamide q3w x 4 → docetaxel q3w x 4). PH q3w was initiated from the start of taxanes and continued after surgery for a total of 17 cycles.

Results

Intention-to-treat population comprised 199 patients in cohort A and 201 in cohort B, with a median follow-up of 64.5 months. No new cardiac safety issues were seen, with few events occurring in the treatment-free period and a low incidence of class III/IV congestive heart failure (Table). Event-free survival (EFS) rates at 5 years were 90.8% (95% CI, 86.5-95.2) and 89.2% (84.8-93.6) in cohorts A and B, respectively. Overall survival rates at 5 years were 96.1% (93.3-98.9) and 93.8% (90.3-97.2) in cohorts A and B, respectively. According to PAM50 classification, available for 339 patients, most patients had HER2-enriched tumors (51.6%), with 5-year EFS rates of 93.1% (87.2-98.9) in cohort A and 88.3% (81.8-94.8) in cohort B

Safety population Cohort A (N=199) Cohort B (N=198)*
No. of patients with at least one LVEF decrease to ≥10% points from baseline to an LVEF <50% (whole study) No. during the treatment-free follow-up period 27 (13.6%) 12 (6.0%) 24 (12.1%)7 (3.5%)
No. of patients with New York Heart Association class III/IV congestive heart failure (whole study)No. during the treatment-free follow-up period 3 (1.5%)0 2 (1.0%)1 (0.5%)

*3 patients without safety data available

.

Conclusions

The final analysis of BERENICE showed sustained cardiac safety and favorable long-term efficacy outcomes, further supporting neoadjuvant/adjuvant PH with standard anthracycline-containing therapies in patients with early stage HER2-positive breast cancer.

Clinical trial identification

NCT02132949 (WO29217), 25 January 2014.

Editorial acknowledgement

Support for third-party writing assistance for this abstract, furnished by Alison McGonagle, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

C. Dang: Honoraria (self): F. Hoffmann-La Roche Ltd., Genentech Inc., Daiichi Sankyo, Lilly, Puma Biotechnology; Advisory/Consultancy: F. Hoffmann-La Roche Ltd., Genentech Inc., Daiichi Sankyo, Lilly, Puma Biotechnology; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. M.S. Ewer: Advisory/Consultancy: AstraZeneca, Bayer, Boehringer Ingelheim; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions.: Roche. S. Delaloge: Advisory/Consultancy: AstraZeneca, Pierre Fabre, BMS, Roche, Lilly, Novartis, Pfizer, Servier, Orion, Puma, Sanofi, Cellectis; Research grant/Funding (institution): AstraZeneca, Roche, GE, Pfizer, Puma, Sanofi, BMS, MSD; Travel/Accommodation/Expenses: Pfizer, Roche, AstraZeneca; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. J-M. Ferrero: Honoraria (self): Pfizer, Lilly, Novartis; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. R. Colomer: Advisory/Consultancy: Roche, Lilly, MSD, AstraZeneca; Research grant/Funding (self): Roche, Lilly, MSD, BMS; Travel/Accommodation/Expenses: Roche, MSD; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. L. de la Cruz Merino: Advisory/Consultancy: MSD, Roche, Celgene; Speaker Bureau/Expert testimony: MSD, Roche, BMS, Amgen; Research grant/Funding (institution): BMS, Roche; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. K. Dadswell: Shareholder/Stockholder/Stock options: Roche; Full/Part-time employment: Roche; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. M. Verrill: Honoraria (self): Roche, Lilly, Pfizer, Novartis, Exact Sciences; Research grant/Funding (institution): Roche, Pfizer, Amgen, Novartis; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. D. Eiger: Research grant/Funding (self): Novartis; Shareholder/Stockholder/Stock options: Roche; Full/Part-time employment: Roche; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. S. Sarkar: Full/Part-time employment, Roche external business partner: PAREXEL; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. S. de Haas: Full/Part-time employment: Roche; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. E. Restuccia: Shareholder/Stockholder/Stock options: Roche; Full/Part-time employment: Roche; Non-remunerated activity/ies, Third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche. S.M. Swain: Honoraria (self): AstraZeneca, Daiichi Sankyo, Roche/Genentech, Exact Sciences (Genomic Health), Molecular Templates, Silverback Therapeutics, Tocagen, Lilly, Natera, Athenex, Bejing Medical Foundation; Advisory/Consultancy: AstraZeneca, Daiichi Sankyo, Roche/Genentech, Exact Sciences (Genomic Health), Molecular Templates, Silverback Therapeutics, Tocagen, Lilly, Natera, Athenex, Bejing Medical Foundation; Advisory/Consultancy, Scientific advisory board: Inivata; Research grant/Funding (institution): Roche/Genentech, Kailos Genetics; Travel/Accommodation/Expenses: BMS, Lilly, Roche/Genentech, Daiichi Sankyo, Caris Life Sciences; Non-remunerated activity/ies, Support for third-party editorial assistance, furnished by Alison McGonagle, PhD, of Health Interactions: Roche.

Collapse
Best abstracts Proffered paper

Invited Discussant 41O, 42O and 43O (ID 236)

Lecture Time
17:52 - 18:07
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30
Best abstracts Proffered paper

Q&A and live discussion (ID 237)

Lecture Time
18:07 - 18:30
Session Name
Room
Channel 1
Date
Fri, 07.05.2021
Time
17:15 - 18:30